The FAERS Public Dashboard and its Value to the Pharmaceutical Industry
Jul 31, 2018 - 00:24:45
Radio and PodcastLive Radio & PodcastsHealth
FDA D.I.S.C.O.: Osimertinib for Non-Small Cell Lung Cancer
FDA medical oncologists discuss the approval of osimertinib for EGFR mutation-positive non-small cell lung cancer. Released July 28, 2017
About This Episode
FDA D.I.S.C.O.: Osimertinib for Non-Small Cell Lung Cancer is an episode from FDA Drug Information Updates by ReachMD. FDA medical oncologists discuss the approval of osimertinib for EGFR mutation-positive non-small cell lung cancer. Releas...
Podcast
This episode belongs to FDA Drug Information Updates.
Listen Online
Use the player on this page to stream the episode online.
Episode Details
Published Jul 28, 2017, 00:06:00 long, audio available.
Related Episodes
Continue listening to more episodes from FDA Drug Information Updates.
FDA Warns of Serious Immune Reaction with Seizure/BPD Medicine Lamotrigine (Lamictal)
May 4, 2018 - 00:02:59
FDA D.I.S.C.O.: First Biosimilar Approval for the Treatment of Cancer
Jan 7, 2018 - 00:08:29
FDA Requires New Class Warnings for All Gadolinium-Based Contrast Agents
Jan 5, 2018 - 00:02:59
The FDA's Adverse Event Reporting System (FAERS) Public Dashboard
Oct 29, 2017 - 00:09:22
FDA D.I.S.C.O.: L-Glutamine for Sickle Cell Disease
Aug 17, 2017 - 00:05:29
FDA D.I.S.C.O.: Two Approvals for ALK-Positive Non-Small Cell Lung Cancer
Jul 25, 2017 - 00:09:00